Eli Lilly Announces Positive Results for Orforglipron in Phase 3 ATTAIN-2 Trial  2025-09-02 
  On August 26, 2025, Eli Lilly and Company announced that their small molecule GLP-1 receptor agonist, Orforglipron, achieved positive results in the third phase 3 clinical trial, ATTAIN-2. 
Read More